{"cluster": 48, "subcluster": 6, "abstract_summ": "29 studies (n=6064) reported gastrointestinal symptoms in patients with COVID-19 at diagnosis, and the pooled prevalence of digestive system comorbidities was 4% (95% CI 2\u20135; range 0\u201315; I(2)=74%).CONCLUSION: Our study has reiterated that GI symptoms are an important clinical feature of COVID-19.Subgroup analysis showed patients with severe COVID-19 had higher rates of gastrointestinal symptoms (odds ratio [OR] 1\u00b760 [95% CI 1\u00b709\u20132\u00b736]; p=0\u00b70020; I(2)=44%) and liver injury (2\u00b720 [1\u00b760\u20133\u00b702]; p<0\u00b700001; I(2)=36%) compared with those with non-severe disease.Extracted data included author; date; study design; country; patient demographics; number of participants in severe and non-severe disease groups; prevalence of clinical gastrointestinal symptoms such as vomiting, nausea, diarrhoea, loss of appetite, abdominal pain, and belching; and digestive system comorbidities including liver disease and gastrointestinal diseases.Among GI symptoms (at onset of illness in 6, at admission in 17, data given separately for both in 3, data unavailable in 52 studies), WPP of diarrhea was 12% (95% CI, 8%-17%), I 2 =94%, nausea and/or vomiting was 9.0% (95% CI, 5.5%-12.9%).", "title_summ": "Another piece of the Zika puzzle: assessing the associated factors to microcephaly in a systematic review and meta-analysisComparison of severe and non-severe COVID-19 pneumonia: review and meta-analysisAGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19, Meta-Analysis of International Data, and Recommendations for the Consultative Management of Patients with COVID-19Prevalence and Mortality of COVID-19 patients with Gastrointestinal Symptoms: A Systematic Review and Meta-analysisImpact of isolation on hospitalised patients who are infectious: systematic review with meta-analysisNovelty in the gut: a systematic review and meta-analysis of the gastrointestinal manifestations of COVID-19A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditionsManifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysisMeta-analysis of outcomes of patients with COVID-19 infection with versus without gastrointestinal symptomsGastrointestinal involvement in COVID-19: a systematic review and meta-analysis", "title_abstract_phrases": "Subgroup analysis showed patients with severe COVID-19 had higher rates of gastrointestinal symptoms (odds ratio [OR] 1\u00b760 [95% CI 1\u00b709\u20132\u00b736]; p=0\u00b70020; I(2)=44%) and liver injury (2\u00b720 [1\u00b760\u20133\u00b702]; p<0\u00b700001; I(2)=36%) compared with those with non-severe disease.Extracted data included author; date; study design; country; patient demographics; number of participants in severe and non-severe disease groups; prevalence of clinical gastrointestinal symptoms such as vomiting, nausea, diarrhoea, loss of appetite, abdominal pain, and belching; and digestive system comorbidities including liver disease and gastrointestinal diseases.29 studies (n=6064) reported gastrointestinal symptoms in patients with COVID-19 at diagnosis, and the pooled prevalence of digestive system comorbidities was 4% (95% CI 2\u20135; range 0\u201315; I(2)=74%).Among GI symptoms (at onset of illness in 6, at admission in 17, data given separately for both in 3, data unavailable in 52 studies), WPP of diarrhea was 12% (95% CI, 8%-17%), I 2 =94%, nausea and/or vomiting was 9.0% (95% CI, 5.5%-12.9%).We performed a meta-analysis comparing the odds of having GI symptoms in severe versus non-severe COVID-19-positive patients."}